<生产厂家 价格>

秋水仙碱

秋水仙碱用途

Colchicine是微管蛋白抑制剂和微管干扰剂。 Colchicine抑制微管聚合的IC50为3 nM。

秋水仙碱名称

[ CAS 号 ]:
64-86-8

[ 中文名 ]:
秋水仙素

[ 英文名 ]:
Colchicine

[中文别名 ]:

[英文别名 ]:

秋水仙碱生物活性

[ 描述 ]:

Colchicine是微管蛋白抑制剂和微管干扰剂。 Colchicine抑制微管聚合的IC50为3 nM。

[ 相关类别 ]:

信号通路 >> 自噬 >> 自噬
信号通路 >> 细胞周期/DNA损伤 >> 微管/微管蛋白
信号通路 >> 细胞骨架 >> 微管/微管蛋白
天然产物 >> 生物碱
研究领域 >> 癌症

[ 靶点 ]

Microtubule/Tubulin[1]


[体外研究]

暴露于1μM秋水仙碱(一种微管破坏剂)在大鼠小脑颗粒细胞(CGC)中引发细胞凋亡。秋水仙碱治疗还会引起Ca2 +对化学去极化反应的改变以及静息细胞内Ca2 +浓度的适度但渐进的增加[1]。秋水仙碱通过与可溶性微管蛋白异二聚体(微管的主要成分)结合而发挥其生物学作用。总结了来自多种来源的微管蛋白结合能力,并深入探讨了秋水仙碱与脑微管蛋白结合的机制。秋水仙素结构与微管蛋白结合活性之间的关系提供了对秋水仙碱的结构特征的了解,其负责与微管蛋白的高亲和力结合,并且对秋水仙碱系列中的类似物进行了综述。根据结合机制描述和评估关联的热力学和动力学方面。秋水仙碱与微管蛋白的结合导致秋水仙碱的低能电子光谱的异常改变。根据秋水仙碱-微管蛋白复合物的性质讨论了与微管蛋白结合的秋水仙碱的光谱特征。提出了在微管蛋白上定位高亲和力秋水仙碱结合位点的尝试[2]。秋水仙碱治疗抑制吲哚美辛诱导的小肠损伤86%(1mg/kg)和94%(3mg/kg),如吲哚美辛给药后24小时的病变指数所示。秋水仙碱抑制裂解的caspase-1和成熟IL-1β的蛋白表达,而不影响NLRP3和IL-1β的mRNA表达[3]。

[体内研究]

在施用吲哚美辛之前30分钟口服施用载体或秋水仙碱(1mg/kg)。在吲哚美辛给药后24小时,在秋水仙碱处理的小鼠中,小肠中伊文思蓝染色的病变小于溶媒处理的小鼠。此外,组织学检查显示,与媒介物处理的小鼠相比,秋水仙碱处理的小鼠具有较少的粘膜炎症和溃疡以及损伤的大小和数量的减少。与媒介物处理相比,秋水仙碱处理在1mg/kg和3mg/kg剂量(分别为86%和94%)下显着降低了病变指数。秋水仙碱处理在1mg/kg和3mg/kg(分别为56%和69%)的剂量下显着抑制成熟IL-1β的蛋白质水平,而不影响pro-IL-1β的那些。秋水仙碱处理还显着抑制切割的半胱天冬酶-1的蛋白质水平,剂量为1 mg/kg和3 mg/kg(分别为26%和39%)而不影响前caspase-1 [3]。

[动物实验]

小鼠[3]使用无特定病原体的8周龄雄性小鼠。使用C57BL / 6背景上的野生型C57BL / 6小鼠和NLRP3 - / - 小鼠。为了检查秋水仙碱对NSAID诱导的小肠损伤的作用,在施用吲哚美辛之前30分钟口服施用载体或秋水仙碱(1或3mg / kg)。在吲哚美辛处理后3小时,小鼠接受腹膜内注射灭菌的磷酸盐缓冲盐水或小鼠重组IL-1β(0.1μg/ kg)。在施用吲哚美辛之前,还向NLRP3 - / - 小鼠施用载体或秋水仙碱(1或3mg / kg)。在给予吲哚美辛后24小时评估病变指数,并在给予吲哚美辛后6小时检查炎性体组分的mRNA和蛋白质表达。

[参考文献]

[1]. Bonfoco E, et al. Colchicine induces apoptosis in cerebellar granule cells. Exp Cell Res. 1995 May;218(1):189-200.

[2]. Hastie SB. Interactions of colchicine with tubulin. Pharmacol Ther. 1991;51(3):377-401

[3]. Otani K, et al. Colchicine prevents NSAID-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Sci Rep. 2016 Sep 2;6:32587.


[相关活性小分子]

诺考达唑 | 一甲基澳瑞他汀E | VcMMAE | Mertansine(DM1化合物) | 甲磺酸艾瑞布林 | 埃博霉素 | 酒石酸长春瑞滨 | 埃博霉素B | McMMAF | MMAF盐酸盐 | 伊沙匹隆 | N,BETA,BETA-三甲基-L-苯基丙氨酰基-N-[(1S,2E)-3-羧基-1-(1-甲基乙基)-2-丁烯基]-N,3-二甲基-L-缬氨酰胺 | 雌莫司汀磷酸钠 | 安丝菌素P3 | 康普瑞汀磷酸二钠

秋水仙碱物理化学性质

[ 密度 ]:
1.3±0.1 g/cm3

[ 沸点 ]:
726.0±60.0 °C at 760 mmHg

[ 熔点 ]:
150-160 °C (dec.)(lit.)

[ 分子式 ]:
C22H25NO6

[ 分子量 ]:
399.437

[ 闪点 ]:
392.9±32.9 °C

[ 精确质量 ]:
399.168182

[ PSA ]:
83.09000

[ LogP ]:
0.92

[ 外观性状 ]:
黄色粉末

[ 蒸汽压 ]:
0.0±2.4 mmHg at 25°C

[ 折射率 ]:
1.585

[ 储存条件 ]:
库房低温,通风,干燥,与食品原料分开存放

[ 水溶解性 ]:
45 g/L (20 ºC)

秋水仙碱MSDS

秋水仙碱毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :
GH0700000
CHEMICAL NAME :
Colchicine
CAS REGISTRY NUMBER :
64-86-8
LAST UPDATED :
199806
DATA ITEMS CITED :
120
MOLECULAR FORMULA :
C22-H25-N-O6
MOLECULAR WEIGHT :
399.48
WISWESSER LINE NOTATION :
L B677 MV&T&J CO1 DO1 EO1 JMV1 NO1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
Standard Draize test
ROUTE OF EXPOSURE :
Administration into the eye
SPECIES OBSERVED :
Rodent - rabbit
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
8360 ug/kg
TOXIC EFFECTS :
Cardiac - other changes Lungs, Thorax, or Respiration - other changes Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
960 ug/kg
TOXIC EFFECTS :
Cardiac - pulse rate increase, without fall in BP
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
1 mg/kg
TOXIC EFFECTS :
Behavioral - hallucinations, distorted perceptions Cardiac - pulse rate increase, without fall in BP Blood - leukopenia
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
320 ug/kg
TOXIC EFFECTS :
Peripheral Nerve and Sensation - flaccid paralysis without anesthesia (usually neuromuscular blockage) Behavioral - muscle weakness Behavioral - muscle contraction or spasticity
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human
DOSE/DURATION :
86 ug/kg
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - other changes Nutritional and Gross Metabolic - body temperature decrease
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
12514 ug/kg/2Y-I
TOXIC EFFECTS :
Behavioral - muscle weakness
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
11 mg/kg
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - respiratory stimulation Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Nutritional and Gross Metabolic - body temperature increase
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
360 ug/kg/6D
TOXIC EFFECTS :
Kidney, Ureter, Bladder - other changes Blood - hemorrhage
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
143 ug/kg/5D-I
TOXIC EFFECTS :
Blood - aplastic anemia Musculoskeletal - other changes
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human
DOSE/DURATION :
129 ug/kg
TOXIC EFFECTS :
Vascular - BP lowering not characterized in autonomic section Vascular - shock Gastrointestinal - hypermotility, diarrhea
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
SPECIES OBSERVED :
Human
DOSE/DURATION :
710 ug/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Vascular - BP lowering not characterized in autonomic section Gastrointestinal - nausea or vomiting
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
4 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - muscle weakness Lungs, Thorax, or Respiration - other changes
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
4 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1600 ug/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - food intake (animal) Gastrointestinal - hypermotility, diarrhea
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intracerebral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1 mg/kg
TOXIC EFFECTS :
Behavioral - tremor Behavioral - convulsions or effect on seizure threshold Behavioral - excitement
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Parenteral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1000 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
5886 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1600 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1200 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1700 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1197 ug/kg
TOXIC EFFECTS :
Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
125 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
571 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
5 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - cat
DOSE/DURATION :
125 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Mammal - cat
DOSE/DURATION :
500 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - cat
DOSE/DURATION :
250 ug/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Gastrointestinal - nausea or vomiting Nutritional and Gross Metabolic - body temperature decrease
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
50 mg/kg
TOXIC EFFECTS :
Gastrointestinal - hypermotility, diarrhea
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
5 mg/kg
TOXIC EFFECTS :
Gastrointestinal - hypermotility, diarrhea
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
3 mg/kg
TOXIC EFFECTS :
Gastrointestinal - hypermotility, diarrhea
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
12500 ug/kg
TOXIC EFFECTS :
Liver - other changes Blood - changes in spleen Blood - other changes
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
500 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - hamster
DOSE/DURATION :
7300 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Bird - pigeon
DOSE/DURATION :
30 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Bird - quail
DOSE/DURATION :
42 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - gerbil
DOSE/DURATION :
90 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Bird - wild bird species
DOSE/DURATION :
31600 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
15500 ug/kg/5W-I
TOXIC EFFECTS :
Gastrointestinal - hypermotility, diarrhea Gastrointestinal - other changes Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Mammal - cat
DOSE/DURATION :
1875 ug/kg/4W-I
TOXIC EFFECTS :
Gastrointestinal - other changes Musculoskeletal - other changes Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
250 ug/kg
SEX/DURATION :
male 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
1200 ug/kg
SEX/DURATION :
female 18-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
1200 ug/kg
SEX/DURATION :
female 18-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
5 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
80 mg/kg
SEX/DURATION :
female 8-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
2500 ug/kg
SEX/DURATION :
male 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
500 ug/kg
SEX/DURATION :
female 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - body wall
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
500 ug/kg
SEX/DURATION :
female 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
1 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
500 ug/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
2 mg/kg
SEX/DURATION :
female 7-10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
1250 ug/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
3750 ug/kg
SEX/DURATION :
female 4-6 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - eye/ear
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
1 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intratesticular
DOSE :
320 mg/kg
SEX/DURATION :
male 2 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
22500 ug/kg
SEX/DURATION :
male 30 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - testes, epididymis, sperm duct
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
4 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
10 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - body wall
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
10 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
1 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intrauterine
DOSE :
2 ug/kg
SEX/DURATION :
female 42 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
Sex chromosome loss and nondisjunction
TYPE OF TEST :
Sex chromosome loss and nondisjunction
TYPE OF TEST :
Micronucleus test
TYPE OF TEST :
Micronucleus test
TYPE OF TEST :
Micronucleus test
TYPE OF TEST :
Micronucleus test
TYPE OF TEST :
Micronucleus test
TYPE OF TEST :
Mutation test systems - not otherwise specified
TYPE OF TEST :
Mutation test systems - not otherwise specified
TYPE OF TEST :
Mutation test systems - not otherwise specified
TYPE OF TEST :
Sex chromosome loss and nondisjunction
TYPE OF TEST :
Sperm Morphology
TYPE OF TEST :
Sperm Morphology
TYPE OF TEST :
Micronucleus test
TYPE OF TEST :
Sex chromosome loss and nondisjunction
TYPE OF TEST :
Micronucleus test

MUTATION DATA

TYPE OF TEST :
DNA inhibition
TEST SYSTEM :
Rodent - rabbit Kidney
DOSE/DURATION :
30 umol/L
REFERENCE :
ECREAL Experimental Cell Research. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.10- 1950- Volume(issue)/page/year: 36,92,1964 *** REVIEWS *** TOXICOLOGY REVIEW KDYIA5 Kidney International. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus Secaucus, NJ 07094) V.1- 1972- Volume(issue)/page/year: 10,82,1976 TOXICOLOGY REVIEW 32XPAD "Teratology," Berry, C.L., and D.E. Poswillo, eds., New York, Springer, 1975 Volume(issue)/page/year: -,49,1975 TOXICOLOGY REVIEW ARVPAX Annual Review of Pharmacology. (Palo Alto, CA) V.1-15, 1961-75. For publisher information, see ARPTDI. Volume(issue)/page/year: 5,447,1965 TOXICOLOGY REVIEW CRTXB2 CRC Critical Reviews in Toxicology. (CRC Press, Inc., 2000 Corporate Blvd., NW, Boca Raton, FL 33431) V.1- 1971- Volume(issue)/page/year: 2,159,1973 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 84682 No. of Facilities: 101 (estimated) No. of Industries: 2 No. of Occupations: 7 No. of Employees: 3397 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 84682 No. of Facilities: 160 (estimated) No. of Industries: 3 No. of Occupations: 12 No. of Employees: 5128 (estimated) No. of Female Employees: 2157 (estimated)

秋水仙碱安全信息

[ 符号 ]:

GHS05, GHS06, GHS08

[ 信号词 ]:
Danger

[ 危害声明 ]:
H300 + H330-H318-H340

[ 警示性声明 ]:
Missing Phrase - N15.00950417-P201-P280-P304 + P340 + P310-P305 + P351 + P338 + P310-P308 + P313

[ 个人防护装备 ]:
Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges

[ 危害码 (欧洲) ]:
T+:Verytoxic;

[ 风险声明 (欧洲) ]:
R26/28

[ 安全声明 (欧洲) ]:
S13-S45

[ 危险品运输编码 ]:
UN 1544 6.1/PG 1

[ WGK德国 ]:
3

[ RTECS号 ]:
GH0700000

[ 包装等级 ]:
I

[ 危险类别 ]:
6.1

秋水仙碱合成路线

秋水仙碱上下游产品

秋水仙碱制备

以山慈姑为原料可以提取秋水仙碱。

将山慈姑粉碎成40~80目粉末,每缸投料60~70kg,加85%~95%乙醇180~210L,加热回流4h,抽滤,再加乙醇回流提取,共3次,第三次抽滤母液套用,第一、二次抽滤液减压浓缩,回收乙醇。将蒸馏残渣加入3~5倍量水,搅匀后放置,等胶质沉淀后用布袋过滤,胶质用水洗涤3次,洗液与滤液合并。滤液用10%硫酸调至pH=2,加氯仿振摇提取至氯仿提取液无色为止,合并氯仿液用5%氢氧化钠溶液约300ml洗涤1次,分取氯仿层,用无水硫酸钠脱水,蒸馏氯仿至近干,得胶状物。取所得胶状物加入5倍量乙酸乙酯中,加热溶解后过滤,放置结晶,抽滤,粗品在低于60℃下干燥得秋水仙碱粗品。秋水仙碱粗品加2倍氯仿,加热溶解后过滤,滤液回收1/2氯仿,放置过夜,抽滤至干,先挥除残留氯仿,再于低温干燥,得秋水仙碱盐结晶。然后再加入5倍量乙酸乙酯,加热溶解,放置结晶,过滤,结晶在低于60℃下干燥,得秋水仙碱成品。

秋水仙碱文献

Deacetyl-mycoepoxydiene, isolated from plant endophytic fungi Phomosis sp. demonstrates anti-microtubule activity in MCF-7 cells.

Biomed. Pharmacother. 69 , 82-9, (2015)

Deacetyl-mycoepoxydiene (DM), a novel secondary metabolite produced by the plant endophytic fungi Phomosis sp., induced the reorganization of cytoskeleton in actively growing MCF-7 cells by promoting ...

Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.

Biochem. Pharmacol. 90(4) , 367-78, (2014)

Cancer cells often become resistant to chemotherapy through a phenomenon known as multidrug resistance (MDR). Several factors are responsible for the development of MDR, preeminent among them being th...

Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing.

Nat. Commun. 6 , 6410, (2015)

In this study, we show that several microtubule-destabilizing agents used for decades for treatment of cancer and other diseases also sensitize cancer cells to oncolytic rhabdoviruses and improve ther...


更多文献

相关化工产品/化学物质:

相关药品:

推荐生产厂家/供应商:

公司名:云南西力生物技术股份有限公司

区域:昆明市盘龙区

价格:
¥需询单/50mg

联系人:郑雪平

产品详情:秋水仙碱


公司名:上海吉至生化科技有限公司

区域:上海市奉贤区

价格:
¥2148.0/5g ¥668.0/1g ¥388.0/500mg ¥148.0/100mg

联系人:刘佳

产品详情:秋水仙碱


公司名:上海如吉生物科技发展有限公司

区域:上海市静安区

价格:
¥150.0/1g

联系人:蕾蕾

产品详情:秋水仙碱


公司名:上海源溪生物科技有限公司

区域:上海市浦东新区

价格:
¥需询单/1g

联系人:赖经理

产品详情:Colchicine


公司名:上海脉铂医药科技有限公司

区域:上海市嘉定区

价格:
¥769.0/1g ¥539.0/1g ¥489.0/250mg ¥639.0/250mg

联系人:李先生

产品详情:Colchicine


查看所有供应商请点击:

秋水仙碱供应商

秋水仙碱相关知识

秋水仙碱说明书-秋水仙碱的副作用

2019-01-12 19:49:39

导读:秋水仙碱[英文名称] colchicine,又名秋水仙素,因最初从百合科植物秋水仙(Colchicum autumnale)中提取出来。秋水仙碱对急性痛风性关节炎有选择性的消炎作用,对一般的疼痛、炎症及慢性痛风均无效。秋水仙碱的毒性较大,常见恶心、呕吐、腹泻、腹痛、胃肠反应是严重中毒的前驱症...


相关化合物

【秋水仙碱】化源网提供秋水仙碱CAS号64-86-8,秋水仙碱MSDS及其说明、性质、英文名、生产厂家、作用/用途、分子量、密度、沸点、熔点、结构式等。CAS号查询秋水仙碱上化源网,专业又轻松。>>电脑版:秋水仙碱

标题:秋水仙碱_MSDS_用途_密度_秋水仙碱CAS号【64-86-8】_化源网 地址:https://www.chemsrc.com/amp/cas/64-86-8_402633.html